Senators Release Report on Hepatitis C Drug Pricing

CSRxP PRESS STATEMENT: Senators Release Report on Hepatitis C Drug Pricing

FOR IMMEDIATE RELEASE
December 1, 2015
Contact: John Rother
Email: [email protected]

Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and senior committee member Chuck Grassley, R-Iowa, today released the results of an 18-month investigation into the pricing and marketing of Gilead Sciences’ Hepatitis C drug Sovaldi and its second-wave successor, Harvoni.

Here’s a statement from John Rother, executive director of the Campaign for Sustainable Rx Pricing in response to the release of the results:

“As we all focus on how to ensure patients get the medications they need at an affordable price, we commend Senators Wyden and Grassley for undertaking this important investigation and for raising awareness around this rapidly growing issue for both sides of the aisle. This comprehensive report documents the company’s disregard for patient access and affordability, showing their only concern is maximizing profit. It is clear that unsustainable and irresponsible drug price tags not only threaten treatment access for millions of patients nationwide, but also put a significant strain on public programs, state budgets, and consumers in need. We thank Senators Wyden and Grassley for this landmark bipartisan effort that helps shed light on harmful pharmaceutical pricing strategies.”